NCT06088290
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
Active, Not Recruiting
PHASE3Ages 18+InterventionalTreatmentPharmaMar
~469 participants
Updated 2026-06-18 on ClinicalTrials.gov
What's tested:LurbinectedinDoxorubicin
At a glance
Recruiting sites
0 of 97 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
PFS by IRC
Measured over Up to approximately 41 months
Conditions
Where it's being run
97 sites across 38 statesSpain15
Italy10
France9
Germany7
United Kingdom7
California5
Austria4
Belgium3
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- PFS by IRCUp to approximately 41 months